Stock Traders Purchase High Volume of Terns Pharmaceuticals Call Options (NASDAQ:TERN)

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) was the recipient of unusually large options trading on Tuesday. Traders purchased 12,742 call options on the stock. This is an increase of approximately 187% compared to the typical daily volume of 4,441 call options.

Analyst Upgrades and Downgrades

TERN has been the topic of several research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $70.00 price objective on shares of Terns Pharmaceuticals in a report on Wednesday, December 10th. Barclays reaffirmed an “equal weight” rating and set a $53.00 price objective (down from $56.00) on shares of Terns Pharmaceuticals in a report on Monday, March 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Terns Pharmaceuticals in a report on Friday, March 27th. Leerink Partners assumed coverage on shares of Terns Pharmaceuticals in a report on Monday, February 9th. They set an “outperform” rating and a $58.00 target price for the company. Finally, Oppenheimer lifted their target price on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Terns Pharmaceuticals has a consensus rating of “Hold” and an average price target of $56.30.

Insider Buying and Selling at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 68,749 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $37.07, for a total transaction of $2,548,525.43. Following the transaction, the chief executive officer owned 288,976 shares of the company’s stock, valued at approximately $10,712,340.32. This represents a 19.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Emil Kuriakose sold 942 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total value of $49,690.50. Following the transaction, the insider directly owned 105,673 shares in the company, valued at approximately $5,574,250.75. This represents a 0.88% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 98,857 shares of company stock worth $3,850,896. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in TERN. Cubist Systematic Strategies LLC grew its holdings in shares of Terns Pharmaceuticals by 136.8% in the 1st quarter. Cubist Systematic Strategies LLC now owns 28,327 shares of the company’s stock valued at $78,000 after buying an additional 16,363 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Terns Pharmaceuticals in the 1st quarter valued at $51,000. Goldman Sachs Group Inc. grew its holdings in shares of Terns Pharmaceuticals by 21.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 415,021 shares of the company’s stock valued at $1,145,000 after buying an additional 71,971 shares during the period. Geode Capital Management LLC grew its holdings in shares of Terns Pharmaceuticals by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company’s stock valued at $6,094,000 after buying an additional 59,145 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Terns Pharmaceuticals by 21.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 358,206 shares of the company’s stock valued at $1,336,000 after buying an additional 64,011 shares during the period. Institutional investors and hedge funds own 98.26% of the company’s stock.

Terns Pharmaceuticals Stock Performance

TERN opened at $52.62 on Wednesday. The company has a fifty day moving average price of $43.67 and a two-hundred day moving average price of $31.60. Terns Pharmaceuticals has a 52 week low of $1.94 and a 52 week high of $53.19. The firm has a market capitalization of $6.07 billion, a PE ratio of -51.09 and a beta of -0.37.

Terns Pharmaceuticals (NASDAQ:TERN) last released its earnings results on Thursday, April 2nd. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.06. Equities analysts forecast that Terns Pharmaceuticals will post -1.19 EPS for the current year.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.